FDA approves first new antibiotic to treat UTIs in nearly 3 decades

Mar 26

Listen

Karah Rucker Anchor

By Karah Rucker (Anchor), Shea Taylor (Producer), Shianne DeLeon (Video Editor)

The FDA approved a new antibiotic to treat urinary tract infections in women and girls 12 and older. The company expects it to be available sometime in 2025.
UTIs are becoming harder to treat as the bacteria that cause them become increasingly antibiotic-resistant.
Nearly all bacteria that cause UTIs are resistant to at least one of the current medications used to treat the infections, and 8 in 10 are resistant to at least two.

Full Story

For the first time in nearly three decades, the Food and Drug Administration approved a new antibiotic for the treatment of urinary tract infections.

Bias Distribution Powered by Ground News™

What do we know about this new treatment?

The company will sell the medicine as a pill under the brand name Bluejepa. The FDA approved the drug for women and girls older than 12 to treat uncomplicated UTIs.

Uncomplicated UTIs are those caused by bacteria and are the most common form of infection.

Download the SAN app today to stay up-to-date with Unbiased. Straight Facts™.

Point phone camera here

Why is this a big deal?

UTIs are becoming harder to treat as the bacteria that cause them become more resistant to the antibiotics currently available to treat them.

The drug’s maker, GSK, said about half of all women will experience a UTI in their lifetime. The company also stated that nearly 30% of women will experience a recurrence even after treatment.

According to the company, UTIs are the cause of roughly 8 million emergency room visits and 100,000 hospitalizations each year in the United States.

GSK’s chief scientific officer said this new medication may be harder for bacteria to become resistant to, as it works by interfering with two enzymes that bacteria need to copy themselves.

A 2019 study out of Saudi Arabia’s Qassim University found more than 92% of bacteria that cause UTIs are resistant to at least one drug used to treat them, and about 80% are resistant to at least two.

When will it be available?

Blujepa is expected to be available by the second half of 2025.

Tags: Drug-resistant infections, FDA, Health, Health Care, hospital, Medication, prescription drugs, saudi arabia, Teen girls, U.S. Food and Drug Administration, United States, Women’s Health

[Karah Rucker]

FOR THE FIRST TIME IN NEARLY THREE DECADES – THE FOOD AND DRUG ADMINISTRATION HAS APPROVED A NEW ANTIBIOTIC FOR THE TREATMENT OF URINARY TRACT INFECTIONS.

THE MEDICINE – A PILL WHICH WILL BE SOLD UNDER THE BRAND NAME BLUJEPA – IS EXPECTED TO BE AVAILABLE BY THE SECOND HALF OF **THIS** YEAR.

IT’S BEEN APPROVED BY THE F-D-A FOR WOMEN AND GIRLS 12 AND OLDER TO TREAT U-T-Is CAUSED BY BACTERIA – THE MOST COMMON FORM OF THE INFECTION.

U-T-Is ARE BECOMING A MORE COMMON PROBLEM AS THE BACTERIA THAT CAUSE THEM BECOME MORE RESISTANT TO THE ANTIBIOTICS CURRENTLY AVAILABLE TO TREAT THEM.

THE DRUG’S MAKER – G-S-K – SAYS ABOUT HALF OF ALL WOMEN WILL EXPERIENCE A U-T-I IN THEIR LIFETIME…

AND NEARLY A THIRD WILL HAVE ONE THAT COMES BACK EVEN AFTER BEING TREATED.

THEY ALSO SAY U-T-Is ARE THE CAUSE OF ROUGHLY 8 MILLION EMERGENCY ROOM VISITS AND 100-THOUSAND HOSPITALIZATIONS EACH YEAR IN THE UNITED STATES.

G-S-K’S CHIEF SCIENTIFIC OFFICER SAYS THIS NEW MEDICATION **MAY** BE HARDER FOR BACTERIA TO BECOME RESISTANT TO – AS IT WORKS BY INTERFERING WITH TWO ENZYMES THAT BACTERIA NEED TO COPY THEMSELVES.

A 20-19 STUDY OUT OD SAUDI ARABIA’S QASSIM (KAH-sim) UNIVERSITY FOUND MORE THAN 92 PERCENT OF BACTERIA THAT CAUSE U-T-Is ARE RESISTANT TO AT LEAST ONE DRUG USED TO TREAT THEM… AND ABOUT 80 PERCENT ARE RESISTANT TO AT LEAST TWO.

TO KEEP UP WITH ALL YOUR LATEST HEALTH HEADLINES MAKE SURE YOUR DOWNLOAD THE STRAIGHT ARROW NEWS APP TODAY.